Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction.

@article{Stahl2009PhaseIC,
  title={Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction.},
  author={Michael Stahl and Martin K. Walz and Martin Stuschke and Nils Lehmann and H-J. Meyer and Jorge Riera-Knorrenschild and Peter Langer and Rita Engenhart-Cabillic and Michael Bitzer and Alfred K{\"o}nigsrainer and Wilfried Budach and Hansjochen Wilke},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 6},
  pages={
          851-6
        }
}
  • M. Stahl, M. Walz, H. Wilke
  • Published 20 February 2009
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE Preoperative chemotherapy is an accepted standard in the treatment of localized esophagogastric adenocarcinoma. Adding radiation therapy to preoperative chemotherapy appears promising, but its definitive value remains unknown. PATIENTS AND METHODS Patients with locally advanced (uT3-4NXM0) adenocarcinoma of the lower esophagus or gastric cardia were randomly allocated to one of two treatment groups: induction chemotherapy (15 weeks) followed by surgery (arm A); or chemotherapy (12… 

Figures and Tables from this paper

Preoperative chemoradiotherapy in locally advanced gastric cancer, a phase I/II feasibility and efficacy study.

  • A. TripB. Poppema G. Hospers
  • Medicine
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • 2014

Preoperative Chemoradiation versus Chemotherapy in Locally Advanced Resectable Esophageal Cancer: A Retrospective Study

TLDR
Despite the non-significant improvement from preoperative chemoradiation with respect to CRM positivity and pathological complete response rates, there was no difference in overall survival or disease-free survival.

Neoadjuvant chemoradiation versus perioperative chemotherapy followed by surgery in resectable adenocarcinomas of the esophagogastric junction: A retrospective single center analysis

TLDR
The results support the use of CRT for patients with advanced AEG tumors as postoperative morbidity and mortality rates were similar in the two groups, and a trend for improved progression-free and overall survival for the CRT group is indicated.

Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis

TLDR
The nCRT confers a better survival with improved R0 resection rate and pCR rate compared with nCT for the patients with locally advanced AEG and no significant difference was observed in postoperative complications between the two groups.

Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma-a pilot study.

TLDR
Preoperative chemoradiotherapy with folfox4 is feasible in locally advanced gej adenocarcinoma, but shows mild efficacy, as suggested by the low rate of pathologic complete response.

Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial.

TLDR
The results do not support unselected addition of radiotherapy to neoadjuvant chemotherapy as a standard of care in patients with resectable esophageal cancer.

Neoadjuvant Chemoradiotherapy Improves Histological Results Compared with Perioperative Chemotherapy in Locally Advanced Esophageal Adenocarcinoma

TLDR
Better histological results were observed in patients who had been treated with CRT, although similar survival rates were observed for patients treated with either CRT or PCT, and further study is necessary to select patients who will benefit most from CRT and PCT.

Comparison of preoperative concurrent chemoradiotherapy with chemotherapy alone in patients with locally advanced siewert II and III adenocarcinoma of the esophagogastric junction.

  • Xueke GeQun Zhao X. Qiao
  • Medicine
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • 2018

Post-neoadjuvant chemoradiotherapy tumor resectability following induction chemotherapy in locally advanced proximal gastric and adenocarcinoma of the esophagogastric junction: A clinical trial

TLDR
Paclitaxel/carboplatin based neoadjuvant chemotherapy was associated with potential resectability and appropriate pathologic response in patients with locally advanced proximal gastric and EGJ adenocarcinoma, but by reducing patient tolerance to complete courses of weekly chemotherapy, induction chemotherapy lowered the effectiveness of concurrent chemotherapy and radiotherapy.

Title A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus ( JCOG 9907 )

TLDR
Preoperative chemotherapy with cisplatin plus 5-fluorouracil can be regarded as standard treatment for patients with stage II/III squamous cell carcinoma.
...

References

SHOWING 1-10 OF 29 REFERENCES

Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.

TLDR
This randomized trial of preoperative chemoradiation versus surgery alone for patients with potentially resectable esophageal carcinoma did not demonstrate a statistically significant survival difference.

Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.

TLDR
Preoperative chemotherapy with a combination of cisplatin and fluorouracil did not improve overall survival among patients with epidermoid cancer or adenocarcinoma of the esophagus.

A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.

TLDR
Multimodal treatment is superior to surgery alone for patients with resectable adenocarcinoma of the esophagus, with the survival advantage favoring multimodal therapy reaching significance at three years.

Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction

TLDR
This investigation investigated the effect of surgery plus postoperative (adjuvant) chemoradiotherapy on the survival of patients with resectable adenocarcinoma of the stomach or gastroesophageal junction.

Signet-Ring Cell or Mucinous Histology after Preoperative Chemoradiation and Survival in Patients with Esophageal or Esophagogastric Junction Adenocarcinoma

TLDR
It is shown that patients with esophageal or EGJ adenocarcinoma who have signet-ring cell or mucinous histology benefited substantially from preoperative chemoradiation and esophagectomy.

Chemotherapy in gastric cancer: a review and updated meta-analysis

TLDR
A meta-analysis of 21 randomised studies that used adjuvant systemic chemotherapy postoperatively found no survival benefit for the treated patients in the western groups, and flaws in the conduct of several trials made it difficult to draw firm conclusions.

American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma.

  • N. RizkE. Venkatraman V. Rusch
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
TLDR
The current AJCC staging system is not a good predictor of survival after CRT, and recursive partitioning analysis more accurately identifies nodal disease and metastatic disease as the most important prognostic variables.